Ruzikowska A
Z III Kliniki Psychiatrycznej IPiN w Warszawie.
Psychiatr Pol. 1996 Jan-Feb;30(1):55-64.
The literature review of combination therapy of schizophrenia with neuroleptics and benzodiazepines is presented. Early trials from the 60s are difficult to evaluate because of the heterogeneity of the patients' groups selected, non-standardized evaluation methods and different diagnostic criteria. The more recent trials, methodologically more correct, were aimed at the allevation by the benzodiazepines of anxiety and agitation symptoms often observed in schizophrenia. The trials aimed at the efficacy of co-therapy with neuroleptics and benzodiazepines, (mainly alprazolam) in schizophrenia were less frequent. As the result, not univocally positive effect of such a therapy was found. The differences in clinical effect might be caused by the individual susceptibility to the anxiolytics. The attempts to correlate various clinical effects of combination therapy with neuroleptics and benzodiazepines and the biological changes in central nervous system in schizophrenia, are also discussed.
本文对精神分裂症使用抗精神病药物和苯二氮䓬类药物联合治疗的文献进行了综述。由于所选患者群体的异质性、评估方法不规范以及诊断标准不同，20世纪60年代的早期试验难以评估。近期的试验在方法上更为正确，旨在通过苯二氮䓬类药物缓解精神分裂症中常见的焦虑和激越症状。针对抗精神病药物和苯二氮䓬类药物（主要是阿普唑仑）联合治疗精神分裂症疗效的试验较少。结果发现这种治疗的效果并非始终呈阳性。临床效果的差异可能是由个体对抗焦虑药的易感性所致。本文还讨论了抗精神病药物和苯二氮䓬类药物联合治疗的各种临床效果与精神分裂症中枢神经系统生物学变化之间的相关性研究。
